This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the initial data for GIST therapies presented at ASCO, including Bezuclastinib in combination with Sunitinib in 2L from Cogent Biosciences THE-630 from Theseus Therapeutics

Ticker(s): COGT, THRX

Who's the expert?

Institution: OHSU Knight Cancer Institute

  • Professor of Medicine at OHSU Knight Cancer Institute.
  • 20 years of experience in preclinical, clinical, and post-translational research in kinase inhibitors, particularly those in GIST and CML.
  • Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.

Interview Questions

Roughly how many GIST patients do you manage?

Added By: wilson_admin

What are your impressions of the Bezuclastinib + sunitinib data so far?

Added By: wilson_admin

What are your impressions of the dose-escalation data from THE-630?

Added By: wilson_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.